13 results about "Asthmatic patient" patented technology

The invention provides a traditional Chinese medicine composition for treating or improving asthma, and relates to the technical field of traditional Chinese medicine pharmacy. The traditional Chinese medicine composition is prepared from the following traditional Chinese medicine raw materials: inula flower, tabasheer, Japanese ardisia herb, cymbopogon distans, ligusticum, pyrrosia lingua, pawpaw, yam rhizome, rhizoma atractylodis, walnut meat, maltose, citron and liquorice. The monarch, minister, assistant and guide in the traditional Chinese medicine composition make the best responsibility, the traditional Chinese medicine composition aims at the symptoms of phlegm-qi obstruction and adverse rising of lung qi of asthma, also has the effects of strengthening the spleen, tonifying the kidney, soothing the liver and the like to consolidate the root cause, has the effects of dispelling wind and ventilating the lung, eliminating phlegm and lowering adverse qi, tonifying the spleen and eliminating dampness, warming the kidney and absorbing qi, and regulating the liver and regulating qi, and has the effects of purgation and tonification and treatment of both symptoms and root causes. The traditional Chinese medicine composition can effectively inhibit airway inflammation reaction of asthma model mice and improve clinical symptoms of the asthma mice, and is remarkable in treatment effect. The traditional Chinese medicine composition disclosed by the invention has a relatively high total effective rate for treating asthma, and has more advantages in the aspects of relieving clinical symptoms of asthma patients and improving lung functions.

Methods for increasing forced expiratory volume in one second (FEV1) in a patient with asthma are presented, comprising administering to the patient an effective amount of benralizumab or an antigen-binding fragment thereof.

The invention discloses a bronchial asthma treatment drug based on RBX1 inhibition and application thereof, and finds that expression of RBX1 in asthma patients and disease models is up-regulated, and the expression level of RBX1 is in positive correlation with airway epithelial barrier injury and active oxygen accumulation degree, which indicates that RBX1 is a key new target for asthma treatment. On the basis of the compound Z226407860 and the compound Z4189742053, the condition that the expression of the RBX1 can be effectively inhibited is further proved. In an in-vitro model, the compounds not only significantly reduce the protein level of RBX1, but also show a good synergistic treatment effect: the compounds can effectively relieve the injury of the airway epithelial barrier and promote the integrity recovery of the barrier, and can inhibit the excessive accumulation of active oxygen at the same time, so that the asthma process is intervened from two correlative core pathological links. The research provides a solid experimental basis and a candidate compound with a clear prospect for developing a therapeutic drug which aims at bronchial asthma and has a brand new action mechanism.

The present invention provides therapeutic agents for treating human asthma through administration of an IL-6 inhibitor to humans. Representative IL-6 inhibitors in the present invention include IL-6 receptor antibodies and IL-6 antibodies. Therapeutic agents of the present invention can yield therapeutic effects in severe asthma patients who need administration of high-dose steroids and such for alleviation of symptoms, or even in patients whose symptoms are difficult to control by common treatment.

To provide methods of increasing forced expiratory volume in one second (FEV1) in an asthma patient.SOLUTION: A method comprises subcutaneously administering an effective amount of benralizumab or an antigen-binding fragment thereof, which is about 2 mg to about 100 mg per dose every 4-12 weeks, where the patient uses a high-dose inhaled corticosteroid (ICS) or long-acting β2 agonist (LABA).SELECTED DRAWING: None

The present application belongs to the technical field of biological medicine, and particularly relates to a pyruvate preparation for asthma treatment and a preparation method thereof. The pyruvate preparation comprises the following components in parts by weight: 10-12 parts of pyruvate, 10-12 parts of sodium chloride, 0.5-1 part of citric acid, and 500 parts of water for injection; and the pH of the pyruvate preparation is 6-7. The pyruvate preparation is used for daily management of asthma patients, can control the increase of inflammatory cells such as eosinophilic granulocyte, reduce inflammatory reaction, and thus achieve the purpose of inhibiting asthma. The effect of the pyruvate preparation is close to that of the same kind of hormone drug dexamethasone, and the pyruvate preparation can achieve the treatment purpose while reducing the dependence of patients on hormone drugs and side effects.

This invention provides a traditional Chinese medicine composition for treating or improving asthma, relating to the field of traditional Chinese medicine pharmaceutical technology. The composition comprises the following raw materials: Inula japonica, Bambusa textilis, Lysimachia christinae, Rutaecarpa, Ligusticum striatum, Pyrrosia lingua, Chaenomeles speciosa, Dioscorea hypoglauca, Atractylodes lancea, walnut kernel, maltose, Citronella arvense, and Glycyrrhiza uralensis. In this invention, each ingredient in the composition fulfills its specific function, addressing both the symptoms of asthma (phlegm and qi stagnation, and upward flow of lung qi) and the underlying causes (spleen strengthening, kidney tonification, and liver soothing). This achieves the combined effects of dispelling wind and clearing the lungs, resolving phlegm and descending rebellious qi, strengthening the spleen and resolving dampness, warming the kidneys and promoting qi circulation, and regulating liver qi. It treats both the symptoms and the root cause. This invention's composition effectively inhibits airway inflammation in asthma model mice, improves clinical symptoms, and demonstrates significant therapeutic effects. The composition exhibits a high overall effective rate in treating asthma, with particular advantages in alleviating clinical symptoms and improving lung function in asthma patients.

The invention belongs to the technical field of biological medicines, and relates to application of an interleukin 33 antibody in preparation of a medicine for relieving asthma aggravation, in particular to application of the interleukin 33 antibody in preparation of a medicine for relieving asthma aggravation induced by ozone exposure. According to the application disclosed by the invention, comprehensive research experiments are adopted, the intervention treatment of the IL-33 antibody is implemented by constructing an asthma model and utilizing an ozone-induced asthma exacerbation model, and the pathophysiological action of the IL-33 antibody in relieving ozone-induced asthma exacerbation is comprehensively disclosed. Experimental results show that the IL-33 antibody can relieve the conditions of asthma mouse lung dysfunction, lung tissue inflammatory cell infiltration and immune cell imbalance in lung tissue caused by ozone exposure. The invention provides a new perspective for the treatment of asthma, and provides a scientific basis and practical value for developing a novel and effective asthma prevention and treatment strategy. The traditional Chinese medicine composition is expected to improve the living quality of asthma patients and reduce health risks caused by environmental pollutants, and has important clinical significance and social value.

The invention relates to a preparation method and application of serum exosome miR-98-5p of an asthma patient, and belongs to the technical field of biological medicine and molecular biology. The preparation method of the serum exosome miR-98-5p of the asthma patient comprises the following steps: S1, collecting the serum of the asthma patient, heating to quickly melt a sample, then performing centrifugal treatment, taking supernate, filtering by a filter membrane, and collecting filtrate; s2, the filtrate is subjected to centrifugal treatment, supernate is removed, and an exosome crude extract is obtained; s3, the exosome crude extract is subjected to centrifugal treatment after being resuspended, supernate is removed, resuspension is conducted, and the serum exosome of the asthma patient is obtained. According to the present invention, BEAS-2B cells are treated by using the serum exosome of an asthma patient, a miR-22-3p mediated TGF-beta / SMAD pathway is down-regulated to participate in cell epithelial-mesenchymal transition, and proliferation and migration of lung epithelial cells BEAS-2B are promoted;

The invention relates to the technical field of aerosol inhalation equipment, in particular to a targeted aerosol inhalation administration device for acute lung injury, which comprises an atomizer, a communicating pipe, a preheating mechanism and an atomizing mechanism, a preheating mechanism is installed above the atomizer, a communicating pipe is arranged in the preheating mechanism, one end of the communicating pipe communicates with the atomizer, and the other end of the communicating pipe communicates with an atomizing mechanism; the preheating mechanism comprises a heating frame fixedly connected with the atomizer, a bottom plate is arranged in the heating frame, a plurality of guide grooves are formed in the bottom plate, springs are arranged in the guide grooves, one end of each spring is fixedly connected with a moving column, and the other end of each spring is fixedly connected with the inner wall of the heating frame; the communicating pipe is preheated, so that the airflow temperature is appropriate, cold fog is prevented from stimulating the airway, uncomfortable symptoms such as cough and bronchus spasm are reduced, and the use tolerance of children, old people, chronic obstructive pulmonary disease patients and asthma patients is improved.

This disclosure provides a peripheral blood plasma biomarker for detecting asthma patients, belonging to the field of biotechnology. The peripheral blood plasma biomarker for detecting asthma patients includes miR-129-2-3p. miR-129-2-3p can serve as a target for the diagnosis and treatment of asthma.

A method for determining a risk of triggering a respiratory disorder compared to a general patient population is disclosed. Data is collected about activations of a medication device for delivering a respiratory medication to a patient population. The activation data and patient context parameter data associated with each activation event are stored. A data analysis module determines the occurrence of rescue events based on the collected activation data and determines a coefficient of the context parameter as a trigger event for a primary patient based on a correlation between the context parameter and the rescue event. The data analysis module provides a comparison of a coefficient of at least one context parameter for the primary patient to a coefficient distribution of trigger events for the patient population based on the correlation between the context parameter and the rescue event for the patient population.

Methods of treating a patient suffering from an interleukin (IL) -33-mediated disorder and methods for determining whether a patient is at increased risk of suffering from an IL-33-mediated disorder or methods for determining whether a patient suffering from a disorder has an increased likelihood of responding to an anti-IL-33 therapy are provided.SOLUTION: A method for treating a patient suffering from asthma, the method comprising administering an IL-33 axis binding antagonist to the patient, wherein the patient's genotype has been determined to comprise at least one allele of a cluster 2 polymorphism defined elsewhere or an equivalent allele at a polymorphism in linkage disequilibrium therewith.SELECTED DRAWING: None